GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price, Quote, News and Overview
NYSE:DNA - New York Stock Exchange, Inc. - US37611X2099 - Common Stock - Currency: USD
DNA Quote, Performance and Key Statistics
NYSE:DNA (2/21/2025, 1:10:55 PM)
11.27
-0.16 (-1.4%)
The current stock price of DNA is 11.27 USD. In the past month the price decreased by -11.4%. In the past year, price decreased by -78.35%.
DNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SHW | SHERWIN-WILLIAMS CO/THE | 30.52 | 87.09B | ||
| ECL | ECOLAB INC | 39.96 | 75.35B | ||
| DD | DUPONT DE NEMOURS INC | 20.14 | 34.27B | ||
| PPG | PPG INDUSTRIES INC | 14.34 | 26.94B | ||
| IFF | INTL FLAVORS & FRAGRANCES | 18.75 | 20.61B | ||
| RPM | RPM INTERNATIONAL INC | 22.87 | 15.61B | ||
| EMN | EASTMAN CHEMICAL CO | 12.61 | 11.53B | ||
| SQM | QUIMICA Y MINERA CHIL-SP ADR | N/A | 11.34B | ||
| ALB | ALBEMARLE CORP | N/A | 9.58B | ||
| AXTA | AXALTA COATING SYSTEMS LTD | 16.23 | 7.93B | ||
| ESI | ELEMENT SOLUTIONS INC | 18.37 | 6.41B | ||
| ALTM | ARCADIUM LITHIUM PLC | 12.67 | 6.27B |
Related stock screener links
About DNA
Company Profile
Ginkgo Bioworks Holdings Inc is a US-based company operating in Chemicals industry. The company is headquartered in Boston, Massachusetts and currently employs 1,218 full-time employees. The company went IPO on 2021-04-19. Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. The company also focuses on the design of next-generation cell therapies for autoimmune diseases. The company uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Company Info
GINKGO BIOWORKS HOLDINGS INC
27 Drydock Avenue, 8th Floor
Boston MASSACHUSETTS US
CEO: Harry E. Sloan
Employees: 1218
Company Website: https://investors.ginkgobioworks.com/
Investor Relations: https://investors.ginkgobioworks.com/
Phone: 18774425362
GINKGO BIOWORKS HOLDINGS INC / DNA FAQ
What is the stock price of GINKGO BIOWORKS HOLDINGS INC today?
The current stock price of DNA is 11.27 USD. The price decreased by -1.4% in the last trading session.
What is the ticker symbol for GINKGO BIOWORKS HOLDINGS INC stock?
The exchange symbol of GINKGO BIOWORKS HOLDINGS INC is DNA and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is DNA stock listed?
DNA stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for GINKGO BIOWORKS HOLDINGS INC stock?
13 analysts have analysed DNA and the average price target is 9.59 USD. This implies a price decrease of -14.92% is expected in the next year compared to the current price of 11.27. Check the GINKGO BIOWORKS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GINKGO BIOWORKS HOLDINGS INC worth?
GINKGO BIOWORKS HOLDINGS INC (DNA) has a market capitalization of 613.99M USD. This makes DNA a Small Cap stock.
How many employees does GINKGO BIOWORKS HOLDINGS INC have?
GINKGO BIOWORKS HOLDINGS INC (DNA) currently has 1218 employees.
What are the support and resistance levels for GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
GINKGO BIOWORKS HOLDINGS INC (DNA) has a support level at 10.07 and a resistance level at 11.43. Check the full technical report for a detailed analysis of DNA support and resistance levels.
Is GINKGO BIOWORKS HOLDINGS INC (DNA) expected to grow?
The Revenue of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to decline by -11.97% in the next year. Check the estimates tab for more information on the DNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DNA, evaluating the profitability, health, valuation and growth aspects
- GINKGO BIOWORKS HOLDINGS INC (DNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GINKGO BIOWORKS HOLDINGS INC (DNA) Sales and EPS estimates to see what analysts future expectations are.
- GINKGO BIOWORKS HOLDINGS INC (DNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GINKGO BIOWORKS HOLDINGS INC (DNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Chart to make your own analysis
- GINKGO BIOWORKS HOLDINGS INC (DNA) Latest news and press-releases to stay up to date.
Does GINKGO BIOWORKS HOLDINGS INC (DNA) stock pay dividends?
DNA does not pay a dividend.
What is the Price/Earnings (PE) ratio of GINKGO BIOWORKS HOLDINGS INC (DNA)?
GINKGO BIOWORKS HOLDINGS INC (DNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.34).
What is the Short Interest ratio of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
The outstanding short interest for GINKGO BIOWORKS HOLDINGS INC (DNA) is 19.93% of its float. Check the ownership tab for more information on the DNA short interest.
DNA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DNA. When comparing the yearly performance of all stocks, DNA is a bad performer in the overall market: 78.28% of all stocks are doing better.
DNA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DNA. While DNA has a great health rating, there are worries on its profitability.
DNA Financial Highlights
Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -11.34. The EPS increased by 37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.97% | ||
| ROE | -81.61% | ||
| Debt/Equity | 0 |
DNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to DNA. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 46.71% and a revenue growth -11.97% for DNA